Clinical trials: Bladder Cancer Treatment
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- GEMCIRAV (NCT00556621)
- Testing
- cisplatin, gemcitabine hydrochloride, biopsy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Bladder Cancer
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive…
- Trial name
- NCT02690558
- Testing
- pembrolizumab, gemcitabine and cisplatin
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Urothelial Carcinoma
The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer
Recently, promising evidences that blocking PD-1 and PD-L1 is an efficacious way to treat advanced stage bladder cancer patients. Atezolimumab is the first PD-L1 inhibitor approved by US FDA for advanced UBC in June 2014.
- Trial name
- NCT03577132
- Testing
- Neoadjuvant atezolizumab
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Urothelial Carcinoma Bladder, Bladder Cancer
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
- Trial name
- NCT06586255
- Testing
- Concurrent Immunotherapy and Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Muscle-Invasive Bladder Carcinoma
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal…
- Trial name
- ARTIA-Vesica (NCT05295992)
- Testing
- Varian Ethos Adaptive Radiation Therapy
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Varian, a Siemens Healthineers Company
Prostate Cancer, Bladder Cancer
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
At the present moment, there is no international consensus on the optimal screening to perform in men with a specific genetic/molecular risk for PCa.
- Trial name
- NCT07265414
- Testing
- Screening Platform
- Where
- Italy
- Volunteers
- 320 people
- Sponsor
- Istituto Clinico Humanitas
Non-muscle Invasive Bladder Cancer
A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
This is an experimental study to evaluate the efficacy and safety of VT-101 for the treatment of non-muscle invasive bladder cancer
- Trial name
- NCT06632964
- Testing
- Recombinant oncolytic adenovirus injection solution of VT-101
- Where
- China
- Volunteers
- 16 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Lymphoma, Digestive System Diseases
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated.
- Conditions
- Lymphoma, Digestive System Diseases, Ovarian Diseases, Pulmonary Disease
- Trial name
- PHRC2003 (NCT00210249)
- Where
- 18 sites in France
- Volunteers
- 364 people
- Sponsor
- Institut Bergonié
Bladder Cancer
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004122
- Testing
- BCG vaccine, recombinant interferon alfa
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa)
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail…
- Conditions
- Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer
- Trial name
- NCT07050771
- Testing
- Comprehensive multimodal prehabilitation (CMMP)
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- The Methodist Hospital Research Institute
Bladder Cancer
Stress-reducing Intervention in Urothelial Carcinoma
The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in…
- Trial name
- NCT06269536
- Testing
- HRV biofeedback
- Where
- Slovakia
- Volunteers
- 50 people
- Sponsor
- Comenius University
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Urinary Bladder Neoplasms, BCG Vaccine
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study
- Trial name
- NCT06441110
- Testing
- Tislelizumab in Combination with Bacillus Calmette-Guérin
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fujian Medical University Union Hospital
Bladder Cancer
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Research Hypothesis Approximately 75% of patients with bladder cancer (BC) present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1) (non-muscle invasive BC [NMIBC]). For high grade NMIBC, i.e.
- Trial name
- NCT03759496
- Testing
- Durvalumab
- Where
- Greece
- Volunteers
- 39 people
- Sponsor
- Hellenic GenitoUrinary Cancer Group
Muscle Invasive Bladder Cancer
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer.
- Trial name
- NCT03773666
- Testing
- Durvalumab, Oleclumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
Non-Muscle-Invasive Bladder cancer (NMIBC) tumours often recur despite TransUrethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) intravesical instillations, and have no effective conservative treatment options.
- Trial name
- PERSEVERANCE (NCT07260162)
- Testing
- ATO-101™
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Cancerologie de l'Ouest
Urothelial Cancer
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
This is an open label, multi-institutional, single arm study of a phase Ib study, followed by a phase II study of durvalumab with radiation therapy (RT) in patients with urothelial cancer (UC).
- Trial name
- DUART (NCT02891161)
- Testing
- durvalumab, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Monika Joshi, MD